Literature DB >> 11144401

Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients.

J L Powers1, W M Gooch, L P Oddo.   

Abstract

BACKGROUND: Patient adherence to therapeutic regimens is extremely important to successful treatment of acute otitis media. Among pediatric patients medication palatability, particularly that of oral suspensions, is essential for patient acceptance, therapeutic compliance and successful outcome.
METHODS: A series of six randomized, single blind, crossover trials were conducted, each comparing cefdinir oral suspension with one of the following antibiotic oral suspensions: amoxicillin/clavulanate potassium; cefprozil; or azithromycin. Each medication comparison was evaluated in a single center and multicenter study. Subjects 4 to 8 years of age were asked to taste and smell each medication and assign preference using a visual "smile-face" scale. Ratings were converted to a numeric score ranging from 5 ("really good") to 1 ("really bad").
RESULTS: Among the 715 subjects 85% rated the taste of cefdinir as good or really good, the highest possible ratings; 63% of subjects assigned the same ratings to amoxicillin/clavulanate potassium, cefprozil or azithromycin. Seventy-one percent rated the smell of cefdinir as good or really good; 64% assigned the same ratings to the comparators.
CONCLUSIONS: Based on the findings from these trials, children 4 to 8 years of age preferred the taste and smell of cefdinir oral suspension to that of the comparator agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144401     DOI: 10.1097/00006454-200012001-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  18 in total

1.  Parent-reported outcomes for treatment of acute otitis media with cefdinir or amoxicillin/clavulanate oral suspensions.

Authors:  Mary A Cifaldi; Maria M Paris; Karen J Devcich; Stanley Bukofzer
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

2.  A Canadian perspective on the American Academy of Pediatrics guidelines for acute otitis media.

Authors:  Marina Salvadori; Fatima Kakkar; Janice Sumpton
Journal:  Paediatr Child Health       Date:  2007-09       Impact factor: 2.253

3.  Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients.

Authors:  Robert Cohen; France de La Rocque; Aurélie Lécuyer; Claudie Wollner; Marie Josée Bodin; Alain Wollner
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

Review 4.  Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use.

Authors:  Maren Preis
Journal:  AAPS PharmSciTech       Date:  2015-03-05       Impact factor: 3.246

Review 5.  Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review.

Authors:  Punam Mistry; Hannah Batchelor
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

6.  Stability, dose uniformity, and palatability of three counterterrorism drugs-human subject and electronic tongue studies.

Authors:  Nakissa Sadrieh; James Brower; Lawrence Yu; William Doub; Arthur Straughn; Stella Machado; Frank Pelsor; Emmanuelle Saint Martin; Terry Moore; John Reepmeyer; Duckhee Toler; Agnes Nguyenpho; Rosemary Roberts; Donald J Schuirmann; Moheb Nasr; Lucinda Buhse
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

7.  Payment analysis of two diagnosis and management approaches of acute otitis media.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Clin Pediatr (Phila)       Date:  2014-05-09       Impact factor: 1.168

Review 8.  Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

Authors:  Jane Easton; Stuart Noble; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Authors:  Jack B Anon; Michael R Jacobs; Michael D Poole; Paul G Ambrose; Mark S Benninger; James A Hadley; William A Craig
Journal:  Otolaryngol Head Neck Surg       Date:  2004-01       Impact factor: 3.497

Review 10.  Design, analysis, and presentation of crossover trials.

Authors:  Edward J Mills; An-Wen Chan; Ping Wu; Andy Vail; Gordon H Guyatt; Douglas G Altman
Journal:  Trials       Date:  2009-04-30       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.